Hirudo (Leech) for proliferative vitreous retinopathy: A protocol for systemic review and meta-analysis
Huang H, Lei R, Li Y, Huang Q, Gao N, Zou W (2021) · Medicine (Baltimore) · n=0
Studienprofil
- Design
- pre-registered systematic review and meta-analysis protocol for Hirudo (leech) or Hirudo-containing Chinese compound prescriptions in proliferative vitreous retinopathy (Chengdu University of Traditional Chinese Medicine, China)
- Stichprobengröße (n)
- —
- Intervention
- Planned synthesis of randomized controlled trials in English or Chinese on Hirudo (leech) and Hirudo-containing compound prescriptions for proliferative vitreous retinopathy (PVR)
- Komparator
- Cross-trial: conventional ophthalmologic care without Hirudo product
- Primärer Endpunkt
- Change in vitreous opacity, vision changes, anterior macular membrane formation, retinal detachment recurrence, and adverse-event incidence
- Primäres Ergebnis
- Pre-registered protocol only - no results yet available; protocol registered at OSF (10.17605/OSF.IO/FP7VG); planned 8-database search including Cochrane, PubMed, MEDLINE, EMBASE, CNKI, CBM, VIP, and Wanfang
- Follow-up-Dauer
- to be determined per included studies
- PMID
- 33546086
Wichtigste Ergebnisse
- First pre-registered systematic review protocol for Hirudo/leech-containing therapeutics in proliferative vitreous retinopathy
- Plans to incorporate Chinese-language databases (CNKI, CBM, VIP, Wanfang) often missing from Western reviews
- Includes both whole-leech therapy and Hirudo-containing Chinese herbal compound prescriptions in scope
- Documents the emerging investigation of leech-derived therapeutics in ophthalmologic indications outside the FDA K040187 clearance
- Pre-registration at OSF supports methodological transparency
Einschränkungen
- Protocol only - no results available at time of registry inclusion
- Scope conflates whole-leech therapy with multi-ingredient Chinese herbal compound prescriptions - mechanistic specificity reduced
- Chinese-language source heterogeneity may produce quality challenges
- PVR is a niche ophthalmologic indication - generalizability to broader leech-therapy literature limited
- Investigators are from a single Chinese TCM institution - external validation pending
Klinische Implikationen
Huang 2021 is a pre-registered systematic review protocol on Hirudo (leech) therapeutics for proliferative vitreous retinopathy. The trial is included in this registry to document the emerging Chinese investigation of leech-derived ophthalmologic indications - a use case largely absent from the Western FDA-cleared K040187 framework. The protocol's ultimate publication will be informative for understanding the global leech-therapy evidence base. ASH editorial team should track the eventual full-publication output of this systematic review.
Verwandte Studien
Effectiveness of leech therapy in osteoarthritis of the knee: a randomized, controlled trial
Michalsen A, Klotz S, Lüdtke R, Moebus S, Spahn G, Dobos GJ (2003)
Leech therapy for symptomatic treatment of knee osteoarthritis: results and implications of a pilot study
Andereya S, Stanzel S, Maus U, Mueller-Rath R, Mumme T, Miltner O (2006)
Comparison of modern leech therapy with intra-articular hyaluronic acid injections for symptomatic relief of knee osteoarthritis
Andereya S, Stanzel S, Maus U, Mueller-Rath R, Mumme T, Miltner O, Andereya S (2008)
A systematic review and meta-analysis of medical leech therapy for osteoarthritis of the knee
Lauche R, Cramer H, Langhorst J, Dobos G (2014)